Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Thrombopoietin-receptor agonists in children with immune thrombocytopenia

Paediatric immune thrombocytopenia is usually a benign condition that results in spontaneous remission within 6–12 months for most of children. Despite severe thrombocytopenia, clinically significant bleeding events are rare. Thus, a common treatment approach for many children is close observation.1 However, a small proportion of children have severe haemorrhage, develop chronic immune thrombocytopenia, are refractory to first-line therapy, or report low health-related quality of life. For these children, development of novel drugs could bring a substantial benefit.

email